GlassScriptPhysician profile
Russell S Pierce
NPI 1093092116
$6,744.35
in general payments reported to CMS, 2019-2025
28 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $640 · 2021: $955 · 2022: $1,075 · 2023: $1,282 · 2024: $1,304 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,655 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,655.26 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,476.33 | 2019-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $1,320.27 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,067.32 | 2021-2025 | |
| Lilly USA, LLC | $503.58 | 2020-2025 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $259.39 | 2020-2025 | |
| Glaxosmithkline, LLC. | $174.28 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Rhythm Pharmaceuticals, INC. | $163.06 | 2022-2025 | Imcivree, Imcivree |
| Merck Sharp & Dohme LLC | $81.81 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.90 | 2019-2025 | |
| Allergan, INC. | $76.99 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $73.64 | 2022 | |
| Xeris Pharmaceuticals, INC. | $56.21 | 2024 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.03 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $44.71 | 2024-2025 | Cologuard Collection Kit |
| Alkermes, INC. | $39.47 | 2024-2025 | Lybalvi, Aristada |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clarus Therapeutics INC. | $37.31 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $26.40 | 2025 | Rexulti |
| Antares Pharma, INC. | $24.63 | 2023 | Xyosted, Tlando, Nocdurna |
| Vivus LLC | $23.94 | 2022 | |
| Ibsa Pharma INC. | $21.14 | 2025 | Flector, Licart, Tirosint |
| Cosette Pharmaceuticals INC. | $20.88 | 2025 | Vyleesi |
| Corcept Therapeutics | $20.55 | 2025 | Korlym |
| Halozyme INC | $19.03 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.68 | 2020 | |
| Vanda Pharmaceuticals INC. | $18.27 | 2025 | Ponvory |
| Aimmune Therapeutics, INC. | $18.11 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $17.95 | 2021 | |
| Axsome Therapeutics, INC. | $13.47 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.